gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CSBRHealthcareBiotechnology

Champions Oncology, Inc. (CSBR)

$4.79−0.83%
Close Nov 5, 2026 · split-adjusted
Nov 3, 2026$4.90▼ 27.94% in range
Nov 3, 2025Low $4.69 · High $7.80Nov 3, 2026
What changed · written from our data
As of Nov 5, 2026

Champions Oncology closed at $4.79 on Nov 5, down 0.83%, within 2.1% of its 52-week closing low. Volume of 9.1K shares was 1.22× its 20-day average (close to normal).

Split-adjusted performance: -1.8% over one month, -20.0% over six months.

In the quarter ended Jul 31, 2026, revenue was $15.23M, up 8.8% from a year earlier, with a net margin of -2.8%.

Short interest was 77.7K shares at the Oct 15 settlement, up 9.4% from the prior report (1.5% of float, 9.4 days to cover).

Market cap$66.7M13.9M shares
Revenue · quarter$15.2M+8.8% YoY
Diluted EPS$-0.03—
P/E · TTM—P/S 1.1×
Net margin-2.8%Gross 50.5%
Dividend yieldNone
52-week range4.69 – 7.80−38.6% from high
Volume9.1K1.22× 20-day avg
Volatility · 60d34.9%Annualised
Short % of float1.5%9.4 days to cover
Net cash$4.4MCash $4.4M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.4%1M −1.8%3M −7.7%6M −20.0%YTD −30.7%1Y —3Y −12.3%5Y −50.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum54
Revenue growth52
Net margin70
Value (low P/E)—
Size30

Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.

Short interest

Details →
Shares short77.7K+9.4% vs prior
Days to cover9.4Settled Oct 15
% of float1.5%
Short vol. 10d28.2%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CSBRChampions Oncology$4.79−0.83%−20.0%+8.8%−2.8%—$66.7M
CGTXCognition Therapeutics$0.6405−6.26%−44.8%———$60.9MCompare
CRDFCardiff Oncology$0.7602−12.51%−52.5%−14.0%−8882.7%—$59.1MCompare
TNYATenaya Therapeutics$0.3400−8.08%−59.9%—−3909.3%—$77.5MCompare
ATRAAtara Biotherapeutics$7.92−5.44%−20.3%−96.4%−767.3%—$79.4MCompare
INKTMiNK Therapeutics$10.10−4.70%−9.7%———$51.6MCompare
ELOXEloxx Pharmaceuticals$12.59−1.18%————$50.8MCompare
KLRSKalaris Therapeutics$2.10+3.96%−59.2%———$50.0MCompare
TVGNTevogen$5.31−7.17%−29.0%———$89.0MCompare

News about Champions Oncology

All news →
CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin GrowthZacks Investment Research · Sep 15, 2026NeutralChampions Oncology (CSBR) Earnings TranscriptThe Motley Fool · Mar 13, 2026Neutral

Quick answers

What does Champions Oncology do?
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services.
What is CSBR's market cap?
$66.67M, based on the Nov 5 close of $4.79.
Does Champions Oncology pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CSBR is sold short?
77.7K shares, 1.5% of float, as of Oct 15, 2026.
What sector is CSBR in?
Healthcare, in the Biotechnology industry.

About Champions Oncology

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.

HQ: Baltimore, MD214 employeesListed Oct 31, 1994championsoncology.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology